|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:ATCCode
|
gptkb:C07AB03
|
|
gptkbp:bioavailability
|
50%
|
|
gptkbp:CASNumber
|
gptkb:29122-68-7
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:halfLife
|
6-7 hours
|
|
gptkbp:hasHydrogenBondAcceptors
|
4
|
|
gptkbp:hasHydrogenBondDonors
|
3
|
|
gptkbp:hasInChIKey
|
METKIMKYRPQLGS-UHFFFAOYSA-N
|
|
gptkbp:hasLogP
|
0.16
|
|
gptkbp:hasMolecularFormula
|
C14H22N2O3
|
|
gptkbp:hasPatent
|
US3729557A
|
|
gptkbp:hasPolarSurfaceArea
|
74.3 Ų
|
|
gptkbp:hasRotatableBonds
|
7
|
|
gptkbp:hasSMILES
|
CC(C)NCC(COC1=CC=CC=C1O)O
|
|
gptkbp:hasTherapeuticUse
|
antianginal agent
antiarrhythmic agent
antihypertensive agent
|
|
gptkbp:hasYearOfFirstApproval
|
1976
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CHEMBL691
|
|
gptkbp:indication
|
gptkb:arrhythmia
myocardial infarction
hypertension
angina pectoris
|
|
gptkbp:isApprovedDrug
|
true
|
|
gptkbp:isOrallyAvailable
|
true
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:listedOn
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:marketedIn
|
gptkb:Europe
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
beta-1 adrenergic receptor antagonist
|
|
gptkbp:meltingPoint
|
152-155°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
266.34
|
|
gptkbp:name
|
gptkb:Atenolol
|
|
gptkbp:notRecommendedFor
|
asthma
severe bradycardia
cardiogenic shock
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
fatigue
bradycardia
cold extremities
|
|
gptkbp:synonym
|
gptkb:Atenololum
gptkb:Tenormin
|
|
gptkbp:target
|
beta-1 adrenergic receptor
|
|
gptkbp:bfsParent
|
gptkb:E2
|
|
gptkbp:bfsLayer
|
5
|